Bio-Rad Laboratories (BIO-B) Change in Account Payables (2009 - 2026)

Bio-Rad Laboratories (BIO-B) has 18 years of Change in Account Payables data on file, last reported at $515.8 million in Q1 2026.

• Quarterly Change in Account Payables rose 5.7% year-over-year to $515.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.1 billion (up 5.08% YoY) and the FY2025 annual result came in at $2.1 billion, changed 0.03% from the prior year.
• Change in Account Payables declined to $515.8 million in Q1 2026 per BIO-B's latest filing, from $547.5 million in the prior quarter.
• Across five years, Change in Account Payables topped out at $620.3 million in Q2 2023 and bottomed at $446.4 million in Q3 2024.
• The 5-year median for Change in Account Payables is $547.5 million (2025), against an average of $546.0 million.
• The widest annual swing landed in 2022, when Change in Account Payables jumped 30.05%; it then retreated 18.67% in 2024.
• Tracing BIO-B's Change in Account Payables over 5 years: stood at $607.5 million in 2022, then retreated by 14.68% to $518.3 million in 2023, then advanced by 1.65% to $526.9 million in 2024, then grew by 3.91% to $547.5 million in 2025, then retreated by 5.79% to $515.8 million in 2026.
• Per Business Quant, the three latest BIO-B Change in Account Payables figures stand at $515.8 million (Q1 2026), $547.5 million (Q4 2025), and $517.5 million (Q3 2025).

Peer Comparison